D. Keating

1.8k total citations · 1 hit paper
53 papers, 1.2k citations indexed

About

D. Keating is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, D. Keating has authored 53 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Pulmonary and Respiratory Medicine, 9 papers in Cardiology and Cardiovascular Medicine and 7 papers in Surgery. Recurrent topics in D. Keating's work include Cystic Fibrosis Research Advances (24 papers), Pulmonary Hypertension Research and Treatments (10 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (7 papers). D. Keating is often cited by papers focused on Cystic Fibrosis Research Advances (24 papers), Pulmonary Hypertension Research and Treatments (10 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (7 papers). D. Keating collaborates with scholars based in Australia, Ireland and United Kingdom. D. Keating's co-authors include Tom Kotsimbos, John Wilson, Timothy Young, Peter Doran, Edward F. McKone, Bonnie W. Ramsey, Elizabeth Tullis, Fengjuan Xuan, Fredrick Van Goor and C Simard and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and CHEST Journal.

In The Last Decade

D. Keating

50 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

2018 500 citations D. Keating, Gautham Marigowda et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D. Keating Australia	16	883	210	143	121	98	53	1.2k
Carmen Sílvia Bertuzzo Brazil	22	659 0.7×	210 1.0×	117 0.8×	187 1.5×	134 1.4×	81	1.1k
Allen Lapey United States	22	1.2k 1.4×	302 1.4×	354 2.5×	126 1.0×	114 1.2×	45	1.7k
Ayşe Boyvat Türkiye	18	337 0.4×	80 0.4×	92 0.6×	47 0.4×	156 1.6×	56	1.3k
Amparo Escribano Spain	18	1.1k 1.3×	125 0.6×	185 1.3×	145 1.2×	260 2.7×	47	1.4k
Jeanne‐Marie Perotin France	15	418 0.5×	147 0.7×	85 0.6×	182 1.5×	79 0.8×	83	823
Mieke Boon Belgium	18	773 0.9×	125 0.6×	67 0.5×	78 0.6×	139 1.4×	60	1.0k
Ivette Buendía-Roldán Mexico	20	863 1.0×	157 0.7×	60 0.4×	271 2.2×	204 2.1×	68	1.2k
Michael S. Stalvey United States	14	451 0.5×	47 0.2×	126 0.9×	25 0.2×	36 0.4×	34	743
Roberta Onesimo Italy	17	115 0.1×	311 1.5×	362 2.5×	70 0.6×	51 0.5×	101	968
Manisha Agarwal India	17	286 0.3×	110 0.5×	63 0.4×	45 0.4×	59 0.6×	45	691

Countries citing papers authored by D. Keating

Since Specialization

Citations

This map shows the geographic impact of D. Keating's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Keating with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Keating more than expected).

Fields of papers citing papers by D. Keating

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Keating. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Keating. The network helps show where D. Keating may publish in the future.

Co-authorship network of co-authors of D. Keating

This figure shows the co-authorship network connecting the top 25 collaborators of D. Keating. A scholar is included among the top collaborators of D. Keating based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Keating. D. Keating is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brown, Karen, David S. Celermajer, Nicholas Collins, et al.. (2023). Impact of Left Heart Disease Risk Factors on Outcomes in Pulmonary Arterial Hypertension Therapy. CHEST Journal. 165(4). 967–977. 3 indexed citations

Williams, E., Brenda Button, Toby Winton‐Brown, et al.. (2022). Cognitive Function in Cystic Fibrosis and CFTR Modulator Therapy. 1–6. 1 indexed citations

Clements, Warren, David C. McGiffin, Heather K. Moriarty, et al.. (2022). Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and massive hemoptysis: The rationale for bronchial artery embolization. Respiratory Medicine. 195. 106784–106784. 4 indexed citations

Wilson, Lisa M, Carol Maher, Matthew J. Ellis, et al.. (2022). Feasibility of the A‐STEP for the assessment of exercise capacity in people with cystic fibrosis. Pediatric Pulmonology. 57(10). 2524–2532. 2 indexed citations

Button, Brenda, Lisa M Wilson, Angela T. Burge, et al.. (2021). The AWESCORE, a patient-reported outcome measure: development, feasibility, reliability, validity and responsiveness for adults with cystic fibrosis. ERJ Open Research. 7(3). 120–2021. 4 indexed citations

Wilson, Lisa M, Matthew J. Ellis, John Wilson, et al.. (2021). Development of the A‐STEP: A new incremental maximal exercise capacity step test in cystic fibrosis. Pediatric Pulmonology. 56(12). 3777–3784. 5 indexed citations

Wilson, John, Xiaojun You, Don S. Urquhart, et al.. (2020). VO2max as an exercise tolerance endpoint in people with cystic fibrosis: Lessons from a lumacaftor/ivacaftor trial. Journal of Cystic Fibrosis. 20(3). 499–505. 19 indexed citations

Keating, D., Gautham Marigowda, Lucy Burr, et al.. (2018). VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. New England Journal of Medicine. 379(17). 1612–1620. 500 indexed citations breakdown →

Keating, D., et al.. (2018). Subclinical Left Ventricular Dysfunction is Influenced by Genotype Severity in Patients with Cystic Fibrosis. SHILAP Revista de lepidopterología. 12. 75457194–75457194. 8 indexed citations

10.

Schneider‐Futschik, Elena K., et al.. (2017). WS13.5 Development of a LC-MS/MS method for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO. Journal of Cystic Fibrosis. 16. S24–S24. 1 indexed citations

11.

Strange, Geoff, Edmund Lau, Eleni Giannoulatou, et al.. (2017). Survival of Idiopathic Pulmonary Arterial Hypertension Patients in the Modern Era in Australia and New Zealand. Heart Lung and Circulation. 27(11). 1368–1375. 24 indexed citations

12.

Peleg, Anton Y., Jocelyn M. Choo, D. Keating, et al.. (2017). Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition. Journal of Cystic Fibrosis. 17(1). 50–56. 33 indexed citations

13.

Keating, D., E. Williams, Brenda Button, et al.. (2015). WS14.1 Ivacaftor improves exercise capacity in patients with G551D CF gene mutations. Journal of Cystic Fibrosis. 14. S27–S27. 2 indexed citations

14.

Keating, D., Glen Westall, Alan Pham, et al.. (2011). Proliferating Bronchial Webs After Lung Transplantation. The Annals of Thoracic Surgery. 92(5). 1893–1896. 5 indexed citations

15.

Salamonsen, Matthew, et al.. (2010). IVI epoprostenol as salvage therapy in pulmonary arterial hypertension: an Australian perspective. Internal Medicine Journal. 41(3). 245–251. 3 indexed citations

16.

Keating, D., Bronwyn Levvey, T. Kotsimbos, et al.. (2008). LUNG TRANSPLANTATION IN PULMONARY FIBROSIS: CHALLENGING EARLY OUTCOMES COUNTERBALANCED BY SURPRISINGLY GOOD OUTCOMES BEYOND 15 YEARS.. Transplantation. 86(2S). 533–533. 4 indexed citations

17.

Malizia, Andrea P., D. Keating, Sinéad M. Smith, et al.. (2008). Alveolar epithelial cell injury with Epstein-Barr virus upregulates TGFβ1 expression. American Journal of Physiology-Lung Cellular and Molecular Physiology. 295(3). L451–L460. 38 indexed citations

18.

Keating, D., Denise M. Sadlier, Sinéad M. Smith, et al.. (2006). Microarray identifies ADAM family members as key responders to TGF-β1 in alveolar epithelial cells. Respiratory Research. 7(1). 114–114. 45 indexed citations

19.

Keating, D., et al.. (2005). Advance Directives for Truth Disclosure. CHEST Journal. 128(2). 1037–1039. 31 indexed citations

20.

Fisher, Daniel F., et al.. (1987). Avascular necrosis of an accessory sesamoid of the foot. A case report. Journal of the American Podiatric Medical Association. 77(11). 612–615. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact